Korro Bio (KRRO) Price & Analysis

Compare

473 Followers

KRRO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.29 - $98.00

Previous CloseN/A

Volume28.02K

Average Volume (3M)116.74K

Market Cap

$150.15M

Enterprise Value$64.56M

Total Cash (Recent Filing)$96.36M

Total Debt (Recent Filing)$44.63M

Price to Earnings (P/E)―

Beta3.18

Next Earnings

Nov 18, 2025

EPS Estimate

-2.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.74

Shares Outstanding9,390,492

10 Day Avg. Volume117,534

30 Day Avg. Volume116,737

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.43

Enterprise Value/Revenue10.28

Enterprise Value/Gross Profit15.31

Enterprise Value/Ebitda-0.68

Forecast

1Y Price Target

$100.50

Price Target Upside430.90% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical ProgressThe AATD clinical trial is progressing and expanding, with two enrollment countries instead of one.

Market PotentialKRRO-110 aims to treat AATD and can confer significant commercial opportunity given the high unmet need and no approved disease-modifying therapies.

Regulatory MilestonesKRRO-110 has been granted orphan drug designation by the European Medicines Agency, which is a positive development for its potential treatment of Alpha-1 Antitrypsin Deficiency.

Bears Say

Clinical And Development RisksRisks include delays in advancing pipeline candidates into and through clinical assessment, failure to generate favorable clinical data from ongoing programs, particularly KRRO-110 in AATD, and possible long-term dilution risk.

Operational RisksManagement announced a restructuring program, aiming to extend the runway into 2027, thereby allowing for clinical readouts/derisking of the two lead programs.

Safety ConcernsSafety remains an important consideration for investors given concerns over potential LNP-mediated safety events, which are believed to be overblown.

Korro Bio News

Korro Bio price target lowered to $90 from $100 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Korro Bio (KRRO) to $90 from $100 and keeps a...

1d ago

KRRO

Korro Bio reports Q2 EPS ($2.74), consensus ($2.59)

Reports Q2 revenue $1.46M, consensus $406.9k. Ram Aiyar, Ph.D., CEO and President of Korro, said, “Throughout the second...

2d ago

KRRO

Korro Bio receives European Medicines Agency granted ODD for KRRO-110

Korro Bio (KRRO) announced that it has been granted orphan drug designation, ODD, by the European Medicines Agency,...

24d ago

KRRO

Korro Bio’s KRRO-110: Promising Safety, Efficacy, and Commercial Potential Drive Buy Rating

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Korro Bio yesterday and set a price target...

1d ago

KRRO

Korro Bio Advances RNA Editing Programs in Q2 2025

Korro Bio, Inc. ( ($KRRO) ) has released its Q2 earnings. Here is a breakdown of the information...

2d ago

KRRO

Buy Rating for Korro Bio Driven by Promising KRRO-110 and Orphan Drug Designation

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Korro Bio, retaining the price target of...

23d ago

KRRO

Korro Bio management to meet with Piper Sandler

Meeting to be held on July 14 hosted by Piper Sandler. Published first on TheFly – the ultimate...

1M ago

KRRO

Korro Bio Elects New Directors at Annual Meeting

Korro Bio ( ($KRRO) ) has provided an update. At the 2025 annual meeting held on June 11,...

2M ago

KRRO

Korro Bio price target lowered to $90 from $155 at Oppenheimer

Oppenheimer lowered the firm’s price target on Korro Bio (KRRO) to $90 from $155 and keeps an Outperform...

3M ago

KRRO

Korro Bio Reports Q1 2025 Financial Results

Korro Bio, Inc. ( ($KRRO) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

KRRO

Korro Bio price target lowered to $53 from $130 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Korro Bio (KRRO) to $53 from $130 and keeps a...

3M ago

KRRO

Korro Bio price target lowered to $100 from $115 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Korro Bio (KRRO) to $100 from $115...

3M ago

KRRO

Strategic Workforce Restructuring and Clinical Advancements Justify Buy Rating for Korro Bio

William Blair analyst Myles Minter has reiterated their bullish stance on KRRO stock, giving a Buy rating on...

3M ago

KRRO

Korro Bio reports Q1 EPS ($2.49), consensus ($2.62)

Reports Q1 revenue $2.55M, consensus $379,000. Ram Aiyar, CEO and President of Korro, said, “We remain on track...

3M ago

KRRO

KRRO FAQ

What was Korro Bio’s price range in the past 12 months?

Korro Bio lowest stock price was $10.29 and its highest was $98.00 in the past 12 months.

What is Korro Bio’s market cap?

Korro Bio’s market cap is $150.15M.

When is Korro Bio’s upcoming earnings report date?

Korro Bio’s upcoming earnings report date is Nov 18, 2025 which is in 96 days.

How were Korro Bio’s earnings last quarter?

Korro Bio released its earnings results on Aug 12, 2025. The company reported -$2.74 earnings per share for the quarter, missing the consensus estimate of -$2.565 by -$0.175.

Is Korro Bio overvalued?

According to Wall Street analysts Korro Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Korro Bio pay dividends?

Korro Bio does not currently pay dividends.

What is Korro Bio’s EPS estimate?

Korro Bio’s EPS estimate is -2.57.

How many shares outstanding does Korro Bio have?

Korro Bio has 9,390,492 shares outstanding.

What happened to Korro Bio’s price movement after its last earnings report?

Korro Bio reported an EPS of -$2.74 in its last earnings report, missing expectations of -$2.565. Following the earnings report the stock price went up 6.246%.

Which hedge fund is a major shareholder of Korro Bio?

Currently, no hedge funds are holding shares in KRRO

Korro Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-58.34%

Trailing 12-Months

Asset Growth

-27.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Korro Bio

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio (KRRO) Earnings & Revenues

Historic Earnings Reports

KRRO Stock 12 Month Forecast

Average Price Target

$100.50

▲(430.90% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","148":"$148","43.75":"$43.8","78.5":"$78.5","113.25":"$113.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":147,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$147.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$100.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,43.75,78.5,113.25,148],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.85,24.092307692307692,34.33461538461538,44.57692307692308,54.81923076923077,65.06153846153846,75.30384615384615,85.54615384615384,95.78846153846153,106.03076923076922,116.27307692307691,126.5153846153846,136.7576923076923,{"y":147,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.85,20.515384615384615,27.18076923076923,33.84615384615385,40.511538461538464,47.17692307692308,53.84230769230769,60.50769230769231,67.17307692307692,73.83846153846154,80.50384615384615,87.16923076923077,93.83461538461538,{"y":100.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.85,18.93846153846154,24.026923076923076,29.115384615384617,34.20384615384616,39.292307692307695,44.38076923076923,49.469230769230776,54.557692307692314,59.64615384615385,64.73461538461538,69.82307692307693,74.91153846153847,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.85,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.49,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.72,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.16,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >